We are live on
!
Find out more
William Blair & Company Portfolio holdings
AUM
$34.9B
1-Year Est. Return
18.88%
This Fund
S&P 500
This Quarter
Est. Return
+5.64%
1 Year Est. Return
+18.88%
3 Year Est. Return
+73.84%
5 Year Est. Return
+90.13%
10 Year Est. Return
+512.03%
AUM
$11.3B
AUM Growth
+$589M
(+5.5%)
Cap. Flow
+$20.5M
Cap. Flow
% of AUM
0.18%
Top 10 Holdings %
Top 10 Hldgs %
17.02%
Holding
1,387
New
148
Increased
486
Reduced
533
Closed
92
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortive
FTV
|
+$47.4M |
| 2 |
AGN
Allergan plc
AGN
|
+$38.9M |
| 3 |
NVRO
NEVRO CORP.
NVRO
|
+$24.1M |
| 4 |
Netflix
NFLX
|
+$21.5M |
| 5 |
Waste Management
WM
|
+$21.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$45.3M |
| 2 |
MDVN
MEDIVATION, INC.
MDVN
|
+$33.2M |
| 3 |
Danaher
DHR
|
+$28.3M |
| 4 |
FLTX
Fleetmatics Group PLC
FLTX
|
+$25.2M |
| 5 |
Healthcare Services Group
HCSG
|
+$24.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.99% |
| 2 | Technology | 15.43% |
| 3 | Financials | 11.87% |
| 4 | Industrials | 11.27% |
| 5 | Consumer Discretionary | 10.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NTUS
976
DELISTED
Natus Medical Inc
NTUS
| $322K | ﹤0.01% |
+8,185
| New | +$326K |
|
977
KB Home
KBH
$3.45B
| $321K | ﹤0.01% |
19,900
| – | – |
|
978
Paycom
PAYC
$7.86B
| $321K | ﹤0.01% |
+6,400
| New | +$313K |
|
979
Stock Yards Bancorp
SYBT
$2.62B
| $321K | ﹤0.01% |
9,733
+287
| +3% | +$8.73K |
|
980
Gen Digital
GEN
$16.9B
| $318K | ﹤0.01% |
12,672
-1,508
| -11% | -$34.3K |
|
|
WBMD
981
DELISTED
WebMD Health Corp.
WBMD
| $318K | ﹤0.01% |
6,393
-800
| -11% | -$44.1K |
|
982
Humana
HUM
$45B
| $317K | ﹤0.01% |
1,792
| – | – |
|
983
abrdn Physical Gold Shares ETF
SGOL
$6.96B
| $317K | ﹤0.01% |
24,740
+5,740
| +30% | +$74.6K |
|
|
ACHN
984
DELISTED
Achillion Pharmaceuticals
ACHN
| $315K | ﹤0.01% |
38,900
+1,500
| +4% | +$12.8K |
|
985
Elevance Health
ELV
$83B
| $314K | ﹤0.01% |
+2,505
| New | +$323K |
|
986
CALL
ExxonMobil
XOM
$643B
| $314K | ﹤0.01% |
+3,600
| New | +$319K |
|
987
Take-Two Interactive
TTWO
$45.8B
| $307K | ﹤0.01% |
+6,800
| New | +$287K |
|
988
Royal Bank of Canada
RY
$292B
| $306K | ﹤0.01% |
4,934
| – | – |
|
989
ProShares Ultra Financials
UYG
$855M
| $302K | ﹤0.01% |
12,450
| – | – |
|
|
BSCK
990
DELISTED
Invesco BulletShares 2020 Corporate Bond ETF
BSCK
| $302K | ﹤0.01% |
+13,900
| New | +$302K |
|
991
Bank of Marin Bancorp
BMRC
$474M
| $298K | ﹤0.01% |
12,000
| – | – |
|
992
Centene
CNC
$31.5B
| $298K | ﹤0.01% |
8,900
-4,814
| -35% | -$167K |
|
993
Dover
DOV
$27.7B
| $298K | ﹤0.01% |
5,003
-171
| -3% | -$9.9K |
|
|
DVAX
994
CALL
DELISTED
Dynavax Technologies
DVAX
| $298K | ﹤0.01% |
+28,400
| New | +$408K |
|
995
State Street SPDR Bloomberg International Treasury Bond ETF
BWX
$1.31B
| $297K | ﹤0.01% |
10,306
+198
| +2% | +$5.69K |
|
996
First Financial Bankshares
FFIN
$5.08B
| $296K | ﹤0.01% |
16,262
-1,600
| -9% | -$28.1K |
|
997
Assembly Biosciences
ASMB
$503M
| $295K | ﹤0.01% |
3,404
| – | – |
|
|
LABL
998
DELISTED
Multi-Color Corp
LABL
| $294K | ﹤0.01% |
4,455
| – | – |
|
999
AllianceBernstein
AB
$3.46B
| $293K | ﹤0.01% |
12,839
+1,200
| +10% | +$27.1K |
|
1000
Quest Diagnostics
DGX
$25.6B
| $293K | ﹤0.01% |
3,465
-16,130
| -82% | -$1.35M |
|
Similar funds
SAM
VIA
William Blair & Company's Q3 2016 Portfolio in Review
As of Q3 2016, William Blair & Company held 1,387 positions worth $11.3B, up 5.5% from $10.7B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
William Blair & Company's Q3 2016 filing shows 148 new, 486 increased, 533 reduced and 92 closed positions. Its largest new stake was Fortive: 1,476,720 shares worth $47.4M. The largest sale was Gilead Sciences, an estimated $45.3M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
- William Blair & Company's largest Q3 2016 buy was Fortive: 1,476,720 shares worth $47.4M.
- William Blair & Company added most to Allergan plc in Q3 2016, an estimated $38.9M increase.
- William Blair & Company's biggest Q3 2016 reduction was Gilead Sciences, cutting an estimated $45.3M.
- William Blair & Company fully exited IHS INC CL-A COM STK in Q3 2016, selling an estimated $6.24M.
- William Blair & Company's ten largest holdings make up 17% of its $11.3B portfolio in Q3 2016.
- William Blair & Company opened 148 new positions and closed 92 in Q3 2016.
- William Blair & Company's portfolio value rose 5.5% quarter-over-quarter to $11.3B.
Based on William Blair & Company's 13F filing for Q3 2016, filed 14 Nov 2016.